36046820|t|Effect of troxerutin in counteracting hyperglycemia-induced VEGF upregulation in endothelial cells: a new option to target early stages of diabetic retinopathy?
36046820|a|Diabetic retinopathy (DR), one of the most common complications of diabetes mellitus, is characterized by degeneration of retinal neurons and neoangiogenesis. Until today, the pharmacological approaches for DR are limited and focused on counteracting the end-stage of this neurodegenerative disease, therefore efforts should be carried out to discover novel pharmacological targets useful to prevent DR development. Hyperglycemia is a major risk factor for endothelial dysfunction and vascular complication, which subsequently may trigger neurodegeneration. We previously demonstrated that, in the rat retina, hyperglycemia activates a new molecular cascade implicating, up-stream, protein kinase C betaII (PKC betaII), which in turn leads to a higher expression of vascular endothelial growth factor (VEGF), via the mRNA-binding Hu-antigen R (HuR) protein. VEGF is a pivotal mediator of neovascularization and a well-known vasopermeability factor. Blocking the increase of VEGF via modulation of this cascade can thus represent a new pharmacological option to prevent DR progression. To this aim, proper in vitro models are crucial for drug discovery, as they allow to better identify promising effective molecules. Considering that endothelial cells are key elements in DR and that hyperglycemia triggers the PKCbetaII/HuR/VEGF pathway, we set up two distinct in vitro models applying two different stimuli. Namely, human umbilical vein endothelial cells were exposed to phorbol 12-myristate 13-acetate, which mimics diacylglycerol whose synthesis is triggered by diabetic hyperglycemia, while human retinal endothelial cells were treated with high glucose for different times. After selecting the optimal experimental conditions able to determine an increased VEGF production, in search of molecules useful to prevent DR development, we investigated the capability of troxerutin, an antioxidant flavonoid, to counteract not only the rise of VEGF but also the activation of the PKCbetaII/HuR cascade in both in vitro models. The results show the capability of troxerutin to hinder the hyperglycemia-induced increase in VEGF in both models through PKCbetaII/HuR pathway modulation. Further, these data confirm the key engagement of this cascade as an early event triggered by hyperglycemia to promote VEGF expression. Finally, the present findings also suggest the potential use of troxerutin as a preventive treatment during the early phases of DR.
36046820	10	20	troxerutin	Chemical	MESH:C005865
36046820	38	51	hyperglycemia	Disease	MESH:D006943
36046820	60	64	VEGF	Gene	7422
36046820	139	159	diabetic retinopathy	Disease	MESH:D003930
36046820	161	181	Diabetic retinopathy	Disease	MESH:D003930
36046820	183	185	DR	Disease	MESH:D003930
36046820	228	245	diabetes mellitus	Disease	MESH:D003920
36046820	368	370	DR	Disease	MESH:D003930
36046820	434	459	neurodegenerative disease	Disease	MESH:D019636
36046820	561	563	DR	Disease	MESH:D003930
36046820	577	590	Hyperglycemia	Disease	MESH:D006943
36046820	618	641	endothelial dysfunction	Disease	MESH:D014652
36046820	646	667	vascular complication	Disease	MESH:D003925
36046820	700	717	neurodegeneration	Disease	MESH:D019636
36046820	759	762	rat	Species	10116
36046820	771	784	hyperglycemia	Disease	MESH:D006943
36046820	843	866	protein kinase C betaII	Gene	25023
36046820	868	878	PKC betaII	Gene	85240
36046820	927	961	vascular endothelial growth factor	Gene	83785
36046820	963	967	VEGF	Gene	83785
36046820	991	1003	Hu-antigen R	Gene	363854
36046820	1005	1008	HuR	Gene	363854
36046820	1019	1023	VEGF	Gene	83785
36046820	1135	1139	VEGF	Gene	83785
36046820	1230	1232	DR	Disease	MESH:D003930
36046820	1433	1435	DR	Disease	MESH:D003930
36046820	1445	1458	hyperglycemia	Disease	MESH:D006943
36046820	1472	1481	PKCbetaII	Gene	85240
36046820	1482	1485	HuR	Gene	1994
36046820	1486	1490	VEGF	Gene	83785
36046820	1579	1584	human	Species	9606
36046820	1634	1665	phorbol 12-myristate 13-acetate	Chemical	MESH:D013755
36046820	1680	1694	diacylglycerol	Chemical	MESH:D004075
36046820	1727	1749	diabetic hyperglycemia	Disease	MESH:D006943
36046820	1757	1762	human	Species	9606
36046820	1812	1819	glucose	Chemical	MESH:D005947
36046820	1924	1928	VEGF	Gene	7422
36046820	1982	1984	DR	Disease	MESH:D003930
36046820	2032	2042	troxerutin	Chemical	MESH:C005865
36046820	2059	2068	flavonoid	Chemical	MESH:D005419
36046820	2105	2109	VEGF	Gene	7422
36046820	2141	2150	PKCbetaII	Gene	85240
36046820	2151	2154	HuR	Gene	1994
36046820	2223	2233	troxerutin	Chemical	MESH:C005865
36046820	2248	2261	hyperglycemia	Disease	MESH:D006943
36046820	2282	2286	VEGF	Gene	7422
36046820	2310	2319	PKCbetaII	Gene	85240
36046820	2320	2323	HuR	Gene	1994
36046820	2438	2451	hyperglycemia	Disease	MESH:D006943
36046820	2463	2467	VEGF	Gene	7422
36046820	2544	2554	troxerutin	Chemical	MESH:C005865
36046820	2608	2610	DR	Disease	MESH:D003930
36046820	Positive_Correlation	MESH:D003930	7422
36046820	Association	MESH:D006943	1994
36046820	Positive_Correlation	MESH:D006943	85240
36046820	Positive_Correlation	83785	85240
36046820	Association	MESH:D004075	MESH:D006943
36046820	Negative_Correlation	MESH:C005865	7422
36046820	Negative_Correlation	MESH:C005865	1994
36046820	Association	1994	83785
36046820	Negative_Correlation	MESH:C005865	MESH:D003930
36046820	Positive_Correlation	MESH:D006943	83785
36046820	Negative_Correlation	MESH:C005865	85240
36046820	Association	MESH:D013755	MESH:D006943
36046820	Positive_Correlation	25023	83785
36046820	Positive_Correlation	MESH:D003930	83785
36046820	Association	MESH:D006943	363854
36046820	Positive_Correlation	MESH:D006943	25023
36046820	Negative_Correlation	MESH:C005865	MESH:D006943
36046820	Positive_Correlation	MESH:D006943	7422
36046820	Association	1994	85240
36046820	Association	363854	83785

